Suppr超能文献

帕利哌酮长效注射剂在精神分裂症患者中的剂量调整和转换:临床实践建议。

Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.

机构信息

Campus Kortenberg, University Psychiatric Centre KU Leuven, Leuvensesteenweg 517, Kortenberg 3070, Belgium.

出版信息

Ann Gen Psychiatry. 2014 Apr 1;13(1):10. doi: 10.1186/1744-859X-13-10.

Abstract

Many patients with schizophrenia receive long-term treatment with antipsychotic medication. Switching of antipsychotic medication due to lack of efficacy, tolerability issues, and partial/non-adherence is common. Despite this, consensus strategies for switching between antipsychotics are lacking. This manuscript provides practical recommendations for switching antipsychotic medication to ensure optimal management of patients with schizophrenia, with a particular focus on paliperidone extended release (ER). The authors drew on their clinical experience supported by detailed discussion of literature describing antipsychotic switching techniques and strategies and findings from paliperidone ER clinical trials. Antipsychotic switching strategies should be individualized and take into consideration the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the pre- and post-switch medication. The use of temporary concomitant medications may be appropriate in some scenarios. Abrupt withdrawal of pre-switch medication may be appropriate in some instances but carries a greater risk of rebound and withdrawal symptoms than other strategies. Cross-tapering is the method most widely used in clinical practice. Paliperidone ER can be initiated without dose titration. The EU SmPC recommended dose of paliperidone ER is 6 mg/day; but doses should be individualized within the approved range of 3-12 mg/day. Higher doses may be required due to insufficient efficacy of the previous antipsychotic or in patients with acute symptoms. Recently diagnosed patients, those with renal impairment, or patients who have previously experienced tolerability issues with other antipsychotics may require lower doses. When switching from risperidone, higher doses of paliperidone ER may be required compared with risperidone. When switching from antipsychotics that have sedative and/or significant anticholinergic activity, the pre-switch antipsychotic should be tapered off gradually. Antipsychotics with less sedating and little anticholinergic activity can be tapered off over a shorter period. Temporary concomitant sedative medication may be beneficial when switching from antipsychotics with relatively higher sedative propensities. Switching from another antipsychotic to paliperidone ER requires individualized switching strategies and dosing, dependent on the characteristics of the patient and the PK and PD properties of the pre-switch medication. Cross-tapering strategies should be considered as a means of reducing the risk of rebound and withdrawal symptoms.

摘要

许多精神分裂症患者需要长期接受抗精神病药物治疗。由于疗效不佳、耐受性问题以及部分/非依从性,常常需要更换抗精神病药物。尽管如此,目前仍缺乏抗精神病药物转换的共识策略。本文提供了确保精神分裂症患者得到最佳管理的抗精神病药物转换实用建议,特别关注了帕利哌酮长效制剂。作者根据文献中描述的抗精神病药物转换技术和策略以及帕利哌酮长效制剂临床试验结果,结合自身的临床经验,提出了这些建议。抗精神病药物转换策略应个体化,并考虑到转换前后药物的药代动力学(PK)和药效动力学(PD)特性。在某些情况下,使用临时伴随药物可能是合适的。在某些情况下,突然停止使用转换前的药物可能是合适的,但与其他策略相比,其反弹和停药症状的风险更大。交叉滴定是临床实践中最广泛使用的方法。帕利哌酮长效制剂可以无需剂量滴定而直接起始使用。欧盟药品说明书推荐的帕利哌酮长效制剂剂量为 6mg/天;但剂量应在批准的 3-12mg/天范围内个体化。对于先前抗精神病药物疗效不足或急性症状患者,可能需要更高的剂量。最近诊断的患者、肾功能损害患者或以前对其他抗精神病药物有耐受性问题的患者可能需要较低的剂量。与利培酮相比,从利培酮转换为帕利哌酮长效制剂时可能需要更高的剂量。从具有镇静和/或明显抗胆碱能活性的抗精神病药物转换时,应逐渐减少转换前的抗精神病药物剂量。镇静作用和抗胆碱能活性较小的抗精神病药物可以在较短的时间内逐渐停药。从镇静作用相对较高的抗精神病药物转换时,临时使用镇静伴随药物可能有益。从另一种抗精神病药物转换为帕利哌酮长效制剂需要个体化的转换策略和剂量,取决于患者的特征以及转换前药物的 PK 和 PD 特性。交叉滴定策略应被视为降低反弹和停药症状风险的一种手段。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8496/3994241/ca662fbcedb0/1744-859X-13-10-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验